Physician profile
Sandra Escandon
NPI 1114985942
$74,024.71
in general payments reported to CMS, 2019-2025
41 companies · $545 in 2025
The $545 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $21K · 2021: $33K · 2022: $11K · 2023: $6,021 · 2024: $542 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,170 · Food and Beverage: $1,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,170.00 |
| Food and Beverage | $1,938.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,033.03 | 2021-2025 | |
| Allergan, INC. | $18,084.38 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $14,704.22 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $12,042.47 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $2,823.50 | 2022 | |
| Pfizer INC. | $245.69 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $233.91 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $183.98 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $165.80 | 2019-2025 | Nuplazid |
| Emd Serono, INC. | $123.73 | 2019 | |
| Impel Pharmaceuticals INC. | $122.10 | 2022 | |
| Amgen INC. | $114.80 | 2019-2024 | Aimovig |
| Lilly USA, LLC | $113.30 | 2019-2024 | Emgality, Reyvow |
| Acorda Therapeutics, INC | $110.64 | 2019-2024 | Inbrija |
| Biogen, INC. | $92.33 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Escandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.